malignancies
Conditions
Interventions
None listed
Sponsors
Yokohama City University hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with any malignancies who were treated with combined D+T are patients of interests. We will not question cancer type because our analysis will focus on AE but not efficacy. We will collected AE data of D+T regimen regardless of dose, scheduling, maintenance therapy, and planned number of doses. Perioperative chemotherapy including both adjuvant and neoadjuvant treatment will be accepted.
Exclusion criteria
Exclusion criteria: Concurrent and sequential chemoradiotherapies will be excluded because anti-cancer drug dosage and safety profile are greatly deviated from D+T alone. Besides, regimen with three or more anti-cancer agents will not be allowed. Consequent treatment of D and T, for example, four doses of D followed by maintenance T, was excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequencies of AEs. | — |
Countries
Japan
Contacts
Public ContactNobuyuki Horita
Yokohama City University Hospital Chemotherapy Center
Outcome results
None listed